Noxopharm Limited 42 Nyrada performance shares (level 3): The 12,000,600 Nyrada performance shares were externally valued considering Level 3 hierarchy fair value inputs such as - the spot price of 13.5 cents, a risk free interest rate of 2.762% (based on Australian government bond rate as a proxy), a historical volatility factor of 78.01% and the Monte Carlo approach for estimating the probability of the market based vesting conditions being achieved. The table below shows the unobservable inputs used in measuring the level 3 fair value of financial instruments in the statement of financial position and the estimated impact of changes to these inputs. Financial instruments with level 3 valuation techniques Significant unobservable inputs Estimated impact on fair value measurement Nyrada performance shares - tranche 1 Volatility of returns of Nyrada CDI’s A +20% increase in the volatility will increase the value of the asset by $90,965 and profit by $90,965. A -20% decrease in the volatility will decrease the value of the asset by ($75,804) and profit ($75,804). Nyrada performance shares - tranche 1 Risk free interest rate A +/-20% movement in the risk free interest rate used in the valuation will have no material impact of on the fair value of the asset or profit. Nyrada performance shares - tranche 2 Volatility of returns of Nyrada CDI’s A +20% increase in the volatility will increase the value of the asset by $90,965 and profit by $90,965 A -20% decrease in the volatility will decrease the value of the asset by ($75,804) and profit ($75,804). Nyrada performance shares - tranche 2 Risk free interest rate A +/-20% movement in the risk free interest rate used in the valuation will have no material impact of on the fair value of the asset or profit.
RkJQdWJsaXNoZXIy MjE2NDg3